ContraFect (NASDAQ:CFRX – Get Rating) was upgraded by analysts at WBB Securities to a “strong-buy” rating in a research note issued on Wednesday, Stock Target Advisor reports. The firm presently has a $7.00 target price on the biotechnology company’s stock. WBB Securities’ price objective points to a potential upside of 104.68% from the company’s current […]
Equities analysts expect ContraFect Co. (NASDAQ:CFRX – Get Rating) to post earnings per share (EPS) of ($0.29) for the current quarter, according to Zacks. Zero analysts have provided estimates for ContraFect’s earnings, with estimates ranging from ($0.31) to ($0.27). ContraFect reported earnings per share of ($0.27) in the same quarter last year, which suggests a […]
StockNews.com began coverage on shares of ContraFect (NASDAQ:CFRX – Get Rating) in a research report issued on Saturday. The brokerage set a “sell” rating on the biotechnology company’s stock. Separately, SVB Leerink dropped their price objective on shares of ContraFect from $14.00 to $9.00 and set an “outperform” rating for the company in a report […]
Brokerages expect that ContraFect Co. (NASDAQ:CFRX – Get Rating) will announce earnings of ($0.33) per share for the current fiscal quarter, according to Zacks. Zero analysts have made estimates for ContraFect’s earnings. The highest EPS estimate is ($0.31) and the lowest is ($0.35). ContraFect posted earnings of ($0.18) per share during the same quarter last […]
ContraFect (NASDAQ:CFRX – Get Rating) posted its earnings results on Thursday. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.26) by $0.15, Fidelity Earnings reports. ContraFect stock opened at $3.84 on Friday. The business’s fifty day simple moving average is $3.09 and its two-hundred […]